CYT-107

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameCYT-107
Drug Alias NameIL-7Second-generation-CYT-99-007Recombinant Human Interleukin-7Lymphopoietin-1Glycosylated recombinant human interleukin-7 +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-7 receptor subunit alpha agonists
TargetsInterleukin-7 receptor subunit alpha
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerSkin Melanoma +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRevimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineRevimmune IncNational Cancer Institute +[4] 
Inactive CompaniesRevImmune SASNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesUrinary Bladder Neoplasms +[13] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerSkin Melanoma +[19] 

Other Information

ATC CodeN/A
Related LinksN/A